Carbocyclic nucleoside hemisulfate and its use in treating viral infections
申请人:Glaxo Wellcome Inc.
公开号:US06294540B1
公开(公告)日:2001-09-25
The hemisulfate salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol or a solvate of it is used in the treatment of viral infections.
A therapeutic method is provided, employing an antiviral compound of the general formula:
wherein Z is HI OR′ or N(R)2, wherein R′ is H, (C1-C4)alkyl, aryl, CHO, (C1-C16)alkanoyl or O═P(OH)2, Y is CH or N, and X is selected from the group consisting of H, N(R)2, SR, OR′ or halogens wherein R is H, lower(C1-C4)alkyl, aryl or mixtures thereof, and the pharmaceutically acceptable salts thereof.
The present invention relates to intermediates to 6-substituted purine carbocyclic nucleosides, which are useful in medical therapy particularly in the treatment of HIV and HBV infections.
本发明涉及 6-取代嘌呤碳环核苷的中间体,这些中间体可用于医疗,特别是治疗 HIV 和 HBV 感染。
Therapeutic nucleosides
申请人:THE WELLCOME FOUNDATION LIMITED
公开号:EP0349242B1
公开(公告)日:1995-03-22
Mehrstufiges Verfahren zur Herstellung von (1S,4R)- und/oder (1R,4S)-4-(2-Amino-6-Chlor-9-H-purin-9-yl)-2-cyclopenten-1-methanol